Antibody-oligonucleotide conjugates depend on targeting ligands that combine specificity, internalisation and developability with conjugation compatibility, a harder bar than target identification alone. This blog sets out how Isogenica's synthetic VHH platform supports AOC discovery: ultra-diverse humanised libraries, fully in vitro selection with real-time NGS monitoring, early developability screening, and site-specific conjugation via single-domain engineering. It also covers how VHHs support scalable production across bacterial, yeast and CHO systems, with half-life extension options built in from the start.
Link:
https://isogenica.com/accelerating-vhh-enabled-aoc-discovery/